Biotech entity
Anne Wojcicki is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 3.7 original sources each against 6.5 for the same window.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Anne Wojcicki is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category. They are less corroborated than the beat average, carrying 3.7 original sources each against 6.5 for the same window. That works out to roughly 1.2 stories per week across an 18-day span. The 7 average consequence score is above the beat benchmark of 6.9 in the same window. This profile follows 3 Biotech stories mentioning 23andMe across the period from July 8, 2026 to July 25, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 83 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering 23andMe. Shared-story counts are live from our verified record — not editorial picks.
23andMe's $46.75 million settlement for the 6.9 million customer data leak highlights the fragility of consumer genetic testing demand. Already in bankruptcy from declining interest, the breach reinforces trust erosion in direct-to-consumer genomics, prompting shifts in industry data stewardship standards.
The $18 million settlement over 6.9 million exposed genetic profiles sends a shockwave through the biotech sector. It underscores how consumer genomics data—once a research treasure trove—can become a career-ending liability when security fails.
Source: greeleytribune.com · broomfieldenterprise.com
For the biotech world, the 23andMe saga is a stark lesson: acquiring assets out of bankruptcy does not shield from inherited data-breach liabilities. Anne Wojcicki’s $305 million purchase now carries a $46.75 million settlement that could chill future investments in consumer genomics.
Source: Kali Hays (gb)
23andMe is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
